Pap test

Lore & Background

The Pap test was independently invented in the 1920s by the Greek physician Georgios Papanikolaou and named after him. The test is performed by opening the vagina with a speculum and collecting cells at the outer opening of the cervix at the transformation zone, using an Ayre spatula or a cytobrush; the collected cells are examined under a microscope to look for abnormalities.

Reader's Guide

The Pap test aims to detect potentially precancerous changes (cervical intraepithelial neoplasia or cervical dysplasia) caused by human papillomavirus, a sexually transmitted DNA virus. When combined with a regular program of screening and appropriate follow-up, the Pap test can reduce cervical cancer deaths by up to 80%. Screening guidelines vary: in general, screening starts about age 20 or 25 and continues until about age 50 or 60, typically every three to five years. Abnormal findings are often followed up by more sensitive diagnostic procedures such as colposcopy or HPV DNA testing. The test remains one of the most effective cervical cancer prevention tools, though it may not prevent adenocarcinoma of the cervix. Failure of prevention can occur due to not getting regular screening, lack of follow-up, or sampling and interpretation errors.

Did You Know?

• The Pap test was independently invented in the 1920s by Greek physician Georgios Papanikolaou.
• The test can reduce cervical cancer deaths by up to 80% when combined with regular screening and appropriate follow-up.
• Over half of all invasive cervical cancers in the US occur in females who have never had a Pap smear.

The Virology Behind the Test

The Pap test exists because of a deceptively simple virus. Human papillomavirus belongs to the Papillomaviridae family and is a DNA virus that, remarkably, is known to infect only humans. Scientists have catalogued more than 200 distinct types, each designated by a number, and a single individual can carry several types simultaneously. Roughly forty of these types are transmitted through sexual contact and target the anus and genitals. Among the most consequential are the so-called high-risk types—about twelve in total, including HPV16, 18, 31, and 45—whose persistent infection has been linked to cancers of the cervix, vulva, vagina, penis, anus, oropharynx, larynx, and throat. HPV16 stands out as the single most carcinogenic strain, present in roughly 47 percent of all cervical cancers and nearly 90 percent of HPV-related cancers of the mouth, throat, and tonsils. Understanding this virological landscape is what gives the Pap test its purpose: detecting the cellular changes these high-risk types trigger before they become irreversible.

Transmission and Risk Factors

HPV spreads primarily through direct skin-to-skin contact, with vaginal and anal intercourse representing the most common routes. Because the virus lives in the outer layers of epithelial tissue, it can be passed even when no visible warts or lesions are present, meaning asymptomatic individuals remain capable of transmitting infection. Beyond sexual contact, a mother can pass HPV to her baby during pregnancy, and although evidence is limited, some studies suggest indirect transfer via contaminated surfaces—so-called fomites—is theoretically possible. The virus resists common hand sanitizers and routine disinfectants, which keeps that fomite pathway from being entirely dismissed. Several factors raise the likelihood that a sexually transmitted HPV infection will persist rather than resolve: initiating sexual activity at a young age, having multiple partners, smoking, and compromised immune function. Despite these risk modifiers, the virus is extraordinarily prevalent. Nearly every sexually active person will encounter HPV at some point, making it the most common sexually transmitted infection worldwide, and approximately ten percent of women are estimated to be currently infected.

The Clinical Spectrum: Warts to Cancer

The consequences of HPV infection span a wide clinical range. Common warts favor hands and feet, plantar warts press inward on the soles causing pain with each step, subungual warts form beneath or around fingernails and prove harder to treat, and flat warts cluster on arms, faces, and foreheads, especially in children and teens. In the genital region, types 6 and 11 account for roughly 90 percent of condylomata acuminata, the medical term for venereal warts. The same two types can also trigger recurrent laryngeal papillomatosis, a rare condition in which warts grow on the larynx or respiratory tract, sometimes obstructing breathing and, in extremely rare instances, progressing to malignancy. At the severe end, persistent high-risk HPV infection drives nearly all cervical cancer and a substantial share of vulvar, vaginal, penile, anal, and oropharyngeal cancers, with HPV16 and HPV18 together responsible for about 70 percent of cervical cases.

Global Burden and the Path to Prevention

The numbers underscore why the Pap test matters on a global scale. Roughly one percent of sexually active adults carry genital warts at any given time, yet the vast majority of genital HPV infections never produce visible symptoms and are cleared by the immune system within months. Prevention and early detection have become central to public health strategy. HPV vaccines now target the most common infecting types, and many health organizations have moved toward direct HPV testing as a screening tool. Because screening enables early treatment of precancerous lesions before they progress, the combination of vaccination and regular testing represents the most effective defense against the full spectrum of HPV-related disease, from benign warts to life-threatening malignancy.